



NDA 019258/S019

SUPPLEMENT APPROVAL

Ecolab, Inc.
Attention: Pete A. Carlson
Senior Regulatory Affairs Specialist
Regulatory Affairs
370 Wabasha St. N
St. Paul, MN 55102-1390

Dear Mr. Carlson:

Please refer to your Supplemental New Drug Application (sNDA) dated November 21, 2011, received, November 22, 2011, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Scrub-Stat™ 2% and Scrub-Stat™ 4% (chlorhexidine gluconate 2% and 4%) solutions.

We acknowledge receipt of your amendments dated February 9, and May 9, 2012.

This “Changes Being Effected” supplemental new drug application provides for changes in the Drug Facts labeling to add directions for use in infants.

We have completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the agreed-upon labeling text and with the following minor editorial revisions:

- a) For all Drug Facts labels: under Directions, move the text “• use with care in premature infants or infants under 2 months of age. These products may cause irritation or chemical burns.” to be the first bulleted statement under Directions.
- b) For the 750-mL (4% only) and 55-gallon (2% and 4%) sizes: under Uses, revise the heading “skin wound and general skin cleansing” to read as “skin wound and general skin cleanser” to be consistent with the other labels.
- c) For the 750-mL (4% only) and 55-gallon (2% and 4%) sizes: under Directions, revise the subheading “Skin wound and general skin cleansing” to read as “Skin wound and general skin cleanser” to be consistent with the other labels.

LABELING

Submit final printed labeling, as soon as they are available, but no more than 30 days after they are printed. The final printed labeling (FPL) must be identical to the following labeling: Scrub-Stat 2% and 4% 4-oz. (118-mL), 18-oz. (540-mL), 27-oz. (750-mL), and 33.8-oz. (1,000-mL) immediate container (bottle) labels, the 2% 33.8-oz. (1,000-mL) immediate container (nozzle bag) label, and the 2% and 4% 55-gallon immediate container (drum) labels submitted on November 21, 2011, and the 2% and 4% 3.78-L (1-gallon) immediate container (bottle) labels submitted May 9, 2012.

This FPL must be in the “Drug Facts” format (21 CFR 201.66), where applicable.

The final printed labeling should be submitted electronically according to the guidance for industry titled “Providing Regulatory Submissions in Electronic Format – Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications (June 2008).” Alternatively, you may submit 12 paper copies, with 6 of the copies individually mounted on heavy-weight paper or similar material. For administrative purposes, designate this submission “**Final Printed Labeling for approved NDA 019258/S019.**” Approval of this submission by FDA is not required before the labeling is used.

DRUG REGISTRATION AND LISTING

All drug establishment registration and drug listing information is to be submitted to FDA electronically, via the FDA automated system for processing structured product labeling (SPL) files (eLIST). At the time that you submit your final printed labeling (FPL), the content of labeling (Drug Facts) should be submitted in SPL format as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>. Information on submitting SPL files using eLIST may be found in the guidance for industry titled “SPL Standard for Content of Labeling Technical Qs and As” at <http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>. In addition, representative container or carton labeling, whichever includes Drug Facts, (where differences exist only in the quantity of contents statement) should be submitted as a JPG file.

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Celia Peacock, Regulatory Project Manager at (301) 796-4154.

Sincerely,

{See appended electronic signature page}

Joel Schiffenbauer, M.D.
Deputy Director
Division of Nonprescription Clinical Evaluation
Office of Drug Evaluation IV
Center for Drug Evaluation and Research

ENCLOSURES

Carton and Container Labeling

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

JOEL SCHIFFENBAUER
05/17/2012